Results 51 to 60 of about 14,435 (170)
Potential drug-drug interactions (DDI) with nirmatrelvir/ritonavir.
, 2023 Potential drug-drug interactions (DDI) with nirmatrelvir/ritonavir.
Grace Ho (4057195) +9 more
core +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins
ChemMedChem, Volume 21, Issue 19, 14 October 2026.Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano +3 more
wiley +1 more source
An Investigation of the Factors Reducing the Use of Hospital Services: A Systematic Review
Health Science Reports, Volume 9, Issue 10, October 2026.ABSTRACT Background and Aims Hospital service utilization has declined in many health systems due to policy shifts, limited resources, and alternative care approaches. This study aimed to systematically review the factors contributing to a reduction in the use or volume of hospital services.
Sedighe Sadat Tabatabaei Far +3 more
wiley +1 more source
COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina [PDF]
In the USA, nirmatrelvir/ritonavir is authorized for the treatment of mild-to-moderate COVID-19 in patients at least 12 years of age, at high risk for progression to severe COVID-19.To estimate the impact of outpatient nirmatrelvir/ritonavir on COVID-19 ...
Napravnik, Sonia +10 more
core +1 more source
PLoS ONE, 2023 BackgroundLarge observational studies have demonstrated the real-world effectiveness of nirmatrelvir-ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use.
Valerie Leung +9 more
doaj +1 more source
<p>Analysis code for the study "Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation"</p ...
IvanAuHKU
core +1 more source
Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models
Journal of Medical Virology, Volume 98, Issue 10, October 2026.ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang +9 more
wiley +1 more source
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
, 2022 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and conflict of interest H. A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of ...
Hannah A. Blair (13864794)
core +1 more source
BMC Infectious DiseasesBackground and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han +20 more
doaj +1 more source